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1. Introduction 
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction caused by 
antibodies directed towards the skeletal muscle nicotinic acetylcholine receptor (AChR), the 
muscle specific kinase (MuSK), and perhaps as yet undefined antigens, which compromise 
neuromuscular transmission (Figure 1) (Vincent et al. 2001; Conti-Fine et al. 2006). The 
disorder has a distinct predilection for the ocular muscles - the extraocular muscles (EOM), 
which move the globe, and the levator palpebrae that elevates the eyelid (Kusner et al. 2006). 
MG may produce weakness of any skeletal muscle to varying degrees with the potential for 
a broad range of clinical presentations (Seybold 1999; Kuks and Oosterhuis 2003); however, 
almost all patients will have ocular manifestations during the disease course, and a large 
subset will have manifestations restricted to the ocular muscles, so-called ocular myasthenia 
(OM) (Kusner et al. 2006). Diagnostic tests for OM include clinical evaluations, serum 
autoantibodies, and electrophysiological evaluation, all of which differ in their diagnostic 
predictive value depending on whether a patient has generalized MG or OM (Roh et al. 
2011). Treatment for OM includes well-studied modalities; however, none that are 
supported by rigorous, controlled trials. This analysis will discuss the ocular manifestations, 
diagnostic testing, and treament of OM, with a focus on the current evidence to support 
clinical decision-making (Luchanok and Kaminski 2008). 
2. Epidemiology 
MG has a prevalence of 20-400 per million based on large population studies, and OM 
comprises approximately 20% of all cases (Somnier et al. 1991; Phillips et al. 1992; 
Christensen et al. 1993; Phillips and Torner 1996; MacDonald et al. 2000; Casetta et al. 2010). 
The classic statement of the disease being of old men and young woman is true with an age 
distribution being bimodal with incidence peaks in the 20’s for women and 40’s for men 
(Phillips and Torner 1996; Grob 1999; Mantegazza et al. 2003; Vincent et al. 2003; Matsuda et 
al. 2005). OM is more likely to present at a later age and is more often seen in men (Gilbert 
and Savino 2007). In Asian populations, OM is more common and has a distinct predilection 
for a juvenile onset, quite different from that observed in European and American 
populations (Chiu et al. 1987; Hawkins et al. 1989; Wong et al. 1992). One study from South 
Africa found that OM in the black population was more likely to be treatment resistant than 
in the white (Heckmann et al. 2007). 
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Fig. 1. Summary of Myasthenia Gravis Pathogenesis. Antibodies directed at neuromuscular 
junction proteins are produced by B cells under T cell regulation. Antibodies compromise 
the AChR density at the neuromuscular junction and thereby impair neuromuscular 
transmission producing weakness. Treatments used for ocular myasthenia are indicated. 
APC-antigen presenting cell. 
3. Ocular manifestations of myasthenia gravis  
Over seventy-five percent of MG patients initially present with ptosis or diplopia and 
almost all MG patients experience ocular manifestations sometime during the course of the 
disease (Beekman et al. 1997; Barton and Fouladvand 2000; Daroff and Benatar 2009). About 
half of patients who present with isolated ocular manifestations develop generalized 
weakness within six months and up to eighty percent will generalize within 2 years (Bever 
et al. 1983; Oosterhuis 1989; Kupersmith et al. 2003). It is likely that symptoms will remain 
restricted to the ocular muscles once a patient has had restricted ocular manifestations for 
over two years (Evoli et al. 1988; Oosterhuis 1989; Grob 1999; Verschuuren et al. 2010).  The 
natural history of the disease impacts therapeutic decision-making. 
The hallmark of MG manifestations is their variable nature, which may range in severity 
over a day, over weeks to months, and include periods of complete resolution. The 
variations in severity assist in diagnostic recognition of MG but may complicate clinical 
recognition, if a patient is examined at a time of relative good strength. Ptosis may be 
unilateral or bilateral, and usually differs in severity between lids. OM is the only diagnostic 
consideration in a patient with a history of alternating or recurrent painless ptosis (Daroff 
and Benatar 2009). Some patients do not immediately appreciate lid droop and complain 
primarily of blurred vision secondary to the lid’s obstruction of the pupil.  Due Hering’s law 
of equal innervation, central compensation for unilateral ptosis may lead to hyper-retraction 
of a less affected lid leading to ocular irritation from exposure. When the ptotic lid is 
manually elevated, the retracted lid droops, a sign commonly considered specific for MG.  
The presence of Cogan’s sign also strongly supports the diagnosis of MG. Cogan’s sign is 
elicited by instructing the patient to look down and then rapidly return the eyes to primary 
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gaze. During the refixation, the eyelid overshoots and appears retracted momentarily and 
then becomes ptotic again (Cogan 1965). 
Other causes of ptosis may rarely be confused with OM. Senile ptosis and levator 
dehiscence are readily differentiated by absence of significant fluctuation. Chronic 
progressive external ophthalmoplegia produces symmetric ptosis and ophthalmoparesis, 
but with slow saccades which should distinguish it from OM (Barton et al. 1995; Leigh 
and Zee 1999; Hirano and DiMauro 2001). Brainstem disorders of the third nerve nuclear 
complex will usually have associated central nervous system pathology. Horner’s 
syndrome is identified by miosis and elevation of the lower lid, while the ptosis in 
complete third nerve palsy is associated with pupillary dilatation. Clinically evident 
pupillary abnormalities never occur in MG, although subclinical alterations in pupillary 
constriction are reported (Tsiptsios et al. 2008).  
Ophthalmoparesis is the second most common manifestation of OM. Most MG patients 
complain of frank double vision; however, complaints may include dizziness, gait instability, 
or visual blurring without significant complaints of diplopia.  Symptoms may improve with 
closure of one eye. Nearly 90% of patients who present with diplopia have associated ptosis, 
and the combination should immediately lead to the consideration of MG as a diagnosis 
(Barton and Fouladvand 2000; Elrod and Weinberg 2004; Fouladvand et al. 2005; Daroff and 
Benatar 2009).  The eye movement abnormalities of MG mimic any peripheral or central 
nervous system ocular motility abnormality, and the degree of impairment varies from 
paralysis to subtle weakness with isolated nystagmus. Dissociated gaze-evoked nystagmus 
contralateral to a paretic eye may be observed in OM, which represents adaptive increases in 
innervational pulse. On dynamic testing, saccadic velocity may be preserved or increased in a 
limited range of movement (highly suggestive of MG) or intrasaccadic fatigue may be 
identified when a fast eye movement suddenly slows and becomes disconjugate in mid-flight 
(Khanna et al. 2007). Graves ophthalmopathy can mimic OM by presence of a restrictive deficit 
but ptosis is absent and if the patient is thyrotoxic, lid retraction may be present. Ptosis in a 
patient with Graves disease suggests the coexistence MG.  
Orbicularis oculi weakness in combination with ptosis or ophthalmoparesis is a strong 
indicator of MG (Barton and Fouladvand 2000; Fouladvand et al. 2005). OM may mimic any 
pupil-sparing ocular motility disorder including fourth, sixth, and partial third nerve 
palsies, and central gaze disorders, such as internuclear ophthalmoplegia, the one and a half 
syndrome, and chronic progressive external ophthalmoplegia (Leigh and Zee 1999; 
Fouladvand et al. 2005; Daroff and Benatar 2009). Other neuromuscular junction disorders 
may mimic OM such as Lambert-Eaton myasthenic syndrome, botulism, or 
organophosphate poisoning, but purely ocular presentations of these disorders are rare. 
Appropriate history, physical examination, and ancillary testing should distinguish these 
conditions from MG. 
4. Diagnostic testing  
The diagnosis of OM may be made based on clinical grounds when no other conditions are 
consistent with a patient’s examination and history. However, at times the clinical 
manifestations are difficult to detect by routine examination or may be absent at time of an 
examination leading to the need for additional evaluation.  In addition, therapy for MG is 
not benign, and most clinicians and patients desire definitive confirmation of the diagnosis. 
However, the clinician must appreciate the limitations of tests used for diagnosis.  
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4.1 Edrophonium test  
The edrophonium test involves intravenous infusion of edrophonium chloride, which 
inhibits the action of acetylcholinesterase (AChE). Procedures for edrophonium 
administration are not standardized, but in general, an initial 1 mg dose is given to assure 
patient tolerance followed by slow infusion over a few minutes until improvement in 
strength of a muscle is observed or a maximum of 10 mg is administered, although 7 mg is 
usually the maximum required to achieve a positive response (Kupersmith et al. 2003). 
Because of the objective nature of the response, unequivocal improvement in strength of a 
ocular muscle is the best endpoint to judge a test as positive (Daroff 1986).  
Improvement of ptosis in response to edrophonium may be as high as 95% and the 
specificity has been reported at 97%; however EOM weakness does not respond as well to 
an edrophonium challenge (Nicholson GA 1983; Evoli et al. 1988; Kupersmith et al. 2003; 
Pascuzzi 2003).  However, these high response rates have been determined in the controlled 
environments of academic institutions and not in standard clinical practices. The specificity 
of the edrophonium is likely to be high as long as the evaluation is performed by 
experienced clinicians. The potential for false positives exists, in the busy office practice, 
especially when the examiner rarely performs such evaluations. Other neuromuscular 
transmission disorders, such as Lambert-Eaton syndrome and botulism, can also cause a 
positive response to edrophonium (Oh SJ 1990), and false positive tests are reported with 
Guillain-Barre syndrome, compressive cranial neuropathies, and brain stem pathology 
(Pascuzzi 2003; Daroff and Benatar 2009).  
There has been concern raised regarding the safety of edrophonium testing, which has led to 
some institutions requiring cardiac monitoring during the procedure. However, serious 
complications of bradycardia and syncope are rare (Ing et al. 2000), and it is the authors’ 
opinion that cardiac monitoring is not necessary for most patients. Cardiac dysrhythmias 
and bronchial asthma are relative contraindications for edrophonium administration. 
Beyond muscarinic effects of tearing, salivation, sweating, abdominal cramps, and nausea, 
the test has limited morbidity (Pascuzzi 2003; Daroff and Benatar 2009).  
4.2 Other clinical evaluations  
The ice pack, rest, and sleep tests are non-pharmacological evaluations, which have been 
developed in order to avoid the need for edrophonium infusion and have close to no 
morbidity. However, the limitation of all these evaluations is that sensitivity and specificity 
assessments have been performed (Benatar 2006). All studies have small sample sizes. Inter-
observer reliability is also not known. 
The ice pack test is performed by placement of an ice pack across the eyes for two to five 
minutes followed by the examiner’s assessment for improvement of ptosis or ocular motility 
deficit (Golnik et al. 1999; Ellis et al. 2000). Some patients may have difficulty tolerating the 
ice pack. The rest test requests the patient close their eyelids for up to 5 minutes, and then 
improvement in ptosis is assessed. For the sleep test, the patient lies with eyes closed in a 
quiet, dark room for 30 minutes and then ptosis and ophthalmoparesis are assessed for 
improvement. For the ice test, sensitivity of 80-97 percent and specificity of 97-100 percent 
are reported (Golnik 1997; Golnik et al. 1999; Benatar 2006). In a study of edrophonium-
positive patients all had positive sleep tests as well (Odell et al. 1991). A small, randomized 
trial compared the ice test to the rest test and found that the median improvement of ptosis 
with the rest test was 2 mm and with the ice test 4.5 mm, but no improvement found among 
www.intechopen.com
 
Ocular Myasthenia Analysis of Diagnostic and Treatment Options 
 
109 
patients without MG (Kubis et al. 2000). One value of these tests is that they may be 
performed in patients in whom edrophonium infusion is contraindicated.  
4.3 Serum autoantibody evaluation  
Serum AChR antibody examinations are performed concurrently, or instead of the clinical 
tests described (Howard et al. 1987). The sensitivity of AChR antibodies testing for OM 
ranges between 39 and 71 percent. The specificity achieved is 95-100 percent (Benatar 2006). 
The detection of AChR antibodies may increase the risk of progression to generalized MG, 
but studies are inconsistent (Seybold 1999; Kupersmith et al. 2003) AChR antibodies have 
been detected without evidence of MG among patients with autoimmune liver disease, 
systemic lupus erythematosus, rheumatoid arthritis, Lambert Eaton syndrome, 
inflammatory neuropathies, amyotrophic lateral sclerosis, thyroid ophthalmopathy, 
thymoma patients, in patients taking D-penicillamine, and first degree relatives of patients 
with MG (Lennon 1997). Therefore, their detection is not absolutely specific for the 
diagnosis. 
The binding AChR antibody is the most sensitive test and the studies described above dealt 
with the binding assay. The modulating AChR antibody may increase the diagnostic yield 
slightly for generalized MG patients but has not been assessed for OM. The modulating 
AChR antibody suffers from higher rates of false positives. The third AChR antibody 
evaluation is the blocking antibody, but it may only slightly increase sensitivity of the 
binding assay. Therefore, the authors generally only order the binding AChR antibody 
examination.  
About a three percent of patients with generalized MG have antibodies against MuSK, a 
neuromuscular junction protein that provides the clustering signal for AChR (Hoch et al. 
2001; Liyanage et al. 2002; Evoli et al. 2003; Vincent et al. 2003; Zhou et al. 2004).  Rare cases 
of pure OM in association with MuSK antibodies are described (Caress et al. 2005; Bennett et 
al. 2006; Chan and Orrison 2007); however, large case series of MuSK antibody positive 
patients have not identified OM patients, but patients may present with ocular manifestions 
(Evoli et al. 2003; Zhou et al. 2004). MuSK examinations are about 16 times the cost of the 
binding AChR antibody test and therefore, should not be routinely requested unless 
clinically indicated.  
Patients with clinical symptoms of MG with electrophysiological evidence of neuromuscular 
junction impairment, but no evidence of serum autoantibodies are deemed to have 
seronegative MG (Argov 2010; Roh et al. 2011). Up to half of OM patients do not have 
detectable antibodies to the AChR. A small percentage (15%) of initially seronegative 
patients may become seropositive for AChR antibodies later in the disease course (Chan et 
al. 2007).  With specialized testing two-thirds of patients with generalized MG without 
traditional antibodies for AChR or MuSK are positive for low-affinity IgG autoantibodies to 
AChR (Leite et al. 2008). Therefore, even in OM patients pathogenic antibodies may be 
directed against the AChR but be undetected by standard testing. 
4.4 Electrodiagnosis  
A significant proportion of OM patients will have negative AChR antibody evaluations 
and have non-definitive clinical assessments. Electrodiagnostic testing needs then to be 
performed to objectively confirm a diagnosis of OM. Repetitive nerve stimulation 
measures the action potential amplitude produced by repetitive low frequency 
stimulation. A decrement of 10% or more is considered positive for MG (Oh SJ 1992). The 
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sensitivity of repetitive nerve stimulation for OM is poor (11-54 percent), but specificity is 
high (89-98 percent) (Roh et al. 2011). Evaluation of the orbicularis oculi (especially the 
lower orbicularis oculi), orbicularis oris, or nasalis will increase the percentage of patients 
identified, but such evaluations are much more difficult to tolerate for patients than 
extremity evaluations (Mercelis and Merckaert 2011). Although identification of 
decremental responses in non-ocular muscles indicates subclinical disease in other 
muscles, the finding does not indicate the presence or predict progression to generalized 
MG.  
Single fiber electromyography (SFEMG) involves repetitive measures of the time between 
action potentials of two fibers in a muscle during a slight contraction. Abnormalities occur 
because of a fiber’s slowed transmission of an action potential because of a compromised 
endplate potential that does not reach threshold. A fiber may not be activated which 
produces a neuromuscular block. If the mean jitter - time between activation of all fiber pairs 
(or endplates) - exceeds the upper limit of normal for that muscle, or if more than 10% of 
pairs have jitter that exceeds the upper limit of jitter during voluntary activation, then the 
study is considered abnormal. SFEMG is 62 to 99 percent sensitive for detection of MG, and 
its specificity is reported to be from 66 to 98 percent (Ukachoke et al. 1994; de 
Entrambasaguas et al. 2007; Mercelis and Merckaert 2011); however, it implementation is 
limited due to the requirements of specially-trained, experienced examiners. Although it is 
labor-intensive, SFEMG should be considered in patients with a strong clinical suspicion for 
OM in which repetitive nerve stimulation is negative, due to its higher sensitivity 
(Srivastava et al. 2007).  The SFEMG is also useful in ruling out myasthenic weakness. If the 
SFEMG is normal in a clinically weak muscle, then the weakness is not due to a 
neuromuscular transmission disorder (Sanders and Stalberg 1996; Katirji and Kaminski 
2002; Meriggioli and Sanders 2004; Sanders 2004).  
4.5 Other evaluations 
When the clinician thinks the OM diagnosis is likely additional testing is necessary. 
Thyroid dysfunction is a common co-morbidity and therefore, it is appropriate to screen 
all OM patients for hypo- or hyperthyroidism. Identification of concurrent thyroid 
dysfunction may improve MG related weakness. If clinically indicated the co-existence of 
other autoimmune disorders should be evaluated, in particular pernicious anemia, Chest 
imaging should be performed to exclude thymoma although thymoma is rare in OM 
patients. In anticipation of immunosuppressive treatments, screening for tuberculosis is 
appropriate. 
5. Treatment 
The treatment goal for patients with OM is to produce normal vision with a minimum of 
adverse effects. Unfortunately, treatment of OM has not been subject to rigorous evaluation 
and longitudinal studies of the risks of chronic treatment do not exist. Also, the individual 
tolerance of patients needs to be considered in making treatment recommendations. Some 
patients with OM respond well to non-pharmacologic therapies that are often overlooked by 
neurologists. If non- pharmacologic therapies cannot provide adequate relief, 
acetylcholesterase are typically administered, but the majority of patients do not respond 
well, and immunosuppressive treatments are required (Table).  
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Drug Cost in USA Mechanism of action 
Pyridostigmine 60 
mg tablets 
 
Pyridostigmine 
180 mg controlled 
release (time 
span)  
$17.99 (30 tabs) 
 
 
$137.99 (30) 
Inhibits acetylcholinesterase at neuromuscular 
junction but also at muscarinic synapses 
Prednisone  
20 mg tablet 
$11.99 (30) Anti-inflammatory effects related to: a) 
redistribution of lymphocytes and reduction of 
production and differentiation, b) alterations of 
function of TNF, IL-1 and IL-2, c) inhibition of 
antigen processing and presentation by 
macrophage. 
Immuran® 50 mg 
tablet 
Azathioprine 50 
mg tablet 
$159.99 (30) 
 
 
$27.99 (30) 
Inhibits T- and B-cell proliferation  
CellCept® 500 mg 
tablet 
Mycophenolate 
mofetil 500 mg 
 $951.33 (100) 
 
 
$129.99 (100) 
Inhibits T- and B-cell proliferation through 
inhibition of guanosine nucleotide synthesis. Also 
produces: a) apoptosis of activated T-
lymphocytes, b) decrease in cell adhesion 
molecules thus reducing lymphocyte recruitment, 
c) reduction of inducible NOS activity. 
Prograf® 1 mg 
capsule 
Tacrolimus 1 mg 
capsule 
$409.94 (100) 
 
$345.97 (100) 
Calcineurin mediated pathway inhibition of T-cell 
and IL-2 production. Modulates the activity of T-
cells, increases their apoptosis and may enhance T 
regulatory cells. 
* From Epocrates® online Searched April 2011.  
Table 1. Ocular Myasthenia Treatment Options  
5.1 Non-pharmaceutical treatment options  
Ptosis may be improved by eyelid tape or crutches; however, patients often are intolerant of 
these approaches finding them uncomfortable. Also, scleral irritation may occur by exposure 
and lead to drying or abrasion. Visual occlusive devices, such as eye patches or opaque 
contact lenses, eliminate diplopia but reduce the visual field. Custom corrective lenses with 
prisms may correct diplopia temporarily, but because patients with OM have fluctuation of 
their visual axes, they require frequent correction of their prism. Prism therapy may be 
considered in patients with stable strabismus for six months to a year. Eye muscle surgery 
may be beneficial in rare patients when a fixed strabismus occurs and non-variable ptosis 
(Ohtsuki et al. 1996; Bentley et al. 2001). Botulinum toxin may also be considered to correct 
ocular alignment by chemodenervation of the involved extraocular muscles, but it must be 
used cautiously given the potential for systemic neuromuscular transmission blockade.  
Although there are challenges associated with the treatments, non-pharmacological options 
may be favored by some patients and be the only options for patients with disease resistant 
to pharmacological treatments.  
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Thymectomy is not generally indicated of OM, but case series do support its use (Schumm 
et al. 1985; Roberts et al. 2001). Of course, OM patients with a thymoma should undergo 
tumor removal and co-incident removal of the remainder of the thymus. 
5.2 Acetylcholesterase inhibition 
AChE inhibitors are the first line of medical treatment for OM, and pyridostigmine is the 
most commonly used drug in the class. While AChE inhibitors are effective for ptosis, 
diplopia is of often resistant to treatment (Sommer et al. 1993; Sommer et al. 1997; 
Mehndiratta et al. 2011).  In some patients, unilateral ptosis “unmasks” ocular misalignment 
producing the symptom of diplopia which may be more troublesome for the patient (Daroff 
and Benatar 2009). Patients presenting with both ptosis and diplopia tend to have an inferior 
response to pyridostigmine (Chirapapaisan N 2007), and many OM patients move on to 
corticosteroid treatment(Kupersmith and Ying 2005).  
Pyridostigmine 30-60 mg three to four times per day are typical starting doses and may be 
increased to 90 to 120 mg every 3-4 hours per day, if symptoms respond and adverse effects 
are kept to a minimum. Complications are primarily related to muscarinic effects, in 
particular abdominal cramps, nausea, vomiting and diarrhea, which occur in at least a third 
of patients (Beekman et al. 1997). Atropine or glycopyrrolate may be used to limit 
muscarinic activity. AChE inhibitor treatment should be used with caution in patients with 
bradycardia and prostatic hypertrophy. Patients with MG treated with AChR inhibitors, 
who have reactive airway disease, may have worsening of respiratory function secondary 
increased respiratory secretions leading to a false conclusion that respiratory insufficiency is 
caused by myasthenic weakness. An open label prospective trial demonstrated improved 
quality of life with the sustained-release form of pyridostigmine, which requires less 
frequent administration (Sieb and Kohler 2010).  However, in the author’s experience, more 
reliable improvements in strength occur with the standard preparation. Cholinergic 
weakness is often discussed but probably does not occur in this era that patients move to 
immunotherapy and do not rely on extremely high doses of AChE inhibitors. However, if a 
clinician is concerned that cholinergic weakness is a cause of worse OM symptoms, the 
AChE inhibitor may be reduced. 
5.3 Corticosteroid treatment 
Most patients will not receive significant benefit from the non-pharmacological and AChE 
inhibitor treatments and will choose to proceed to immunosuppressive treatment 
(Kupersmith and Ying 2005).  Prednisone is the most frequently used immunosuppressive 
treatment for OM, and unless corticosteroids are contraindicated due to comorbities, it is the 
first-line immunosuppressive for OM. Although this is based on retrospective 
analysis(Benatar and Kaminski 2007, Bhanushali et al. 2008).  
Dosing regimens vary but typically, 10-20 mg once a day is started and increased by 5-10 mg 
every 3 days until visual symptoms are improved significantly, which usually occurs in the 
first few weeks of therapy (Kupersmith et al. 2003; Mee et al. 2003; Papapetropoulos et al. 
2003). 60-80 mg per day is a maximum dose. At times mild double vision that does not 
impair function may persist and need to be tolerated. After symptom resolution is 
maintained for a month, a slow taper is instituted at a rate of 5-10 mg per day every 2 weeks 
until a dose of 20 mg every day is achieved and the dose reductions slowed further. Rapid 
tapers often lead to recurrence of symptoms, but even with gradual dose reductions a large 
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percentage of patients will have symptom recurrence. Patients will need an increase in dose 
when symptoms recur. Most patients require maintenance doses for years, which should be 
the lowest possible to prevent recurrence of visual complaints. More than three-quarters of 
patients experience significant improvement (Evoli et al. 1988; Sommer et al. 1997; 
Tackenberg et al. 2001; Kupersmith and Ying 2005).  To reduce corticosteroid complications 
every other day dosing of prednisone may be used. Patients should be instructed to take a 
single morning dose, which mimics the diurnal peak of endogenous corticosteroid. Patients 
need to be educated about steroid side effects, which include weight gain, glucose tolerance, 
hypertension, osteoporosis, insomnia, anxiety, depression, and the numerous other 
complications of prednisone. The neurologist or ophthalmologist should work with the 
patient’s primary care physician to monitor for complications.  
Based on retrospective analysis, corticosteroids may delay or prevent the progression of OM 
to generalized MG (Agius 2000; Kaminski and Daroff 2000; Kupersmith 2004). However, 
there has not been a randomized, controlled trial to assess whether steroids have a disease 
modifying effect (Gilbert et al. 2007; Gilbert and Savino 2007). Future studies should 
consider visual outcome and quality of life to determine whether the benefits of 
corticosteriods outweigh the complications of chronic corticosteroid use. 
5.4 Immunotherapy 
Some patients will not respond to corticosteroids, have contraindications to their use, or 
have intolerable adverse effects necessitating use of other immunotherapies (Tackenberg et 
al. 2001).  Assessment of efficacy for immunosuppressives specific to treatment for OM is 
extremely limited and is entirely based on retrospective investigation.  Support for their use 
also derives from administration for the generalized disease, but these studies are also not 
robust. Azathioprine was demonstrated to reduce corticosteroid requirements in a 
randomized, placebo-controlled trial of generalized MG patients (Palace et al. 1998), and 
retrospective analyses support its efficacy in OM patients (Mertens et al. 1981; Matell 1987; 
Hohlfeld et al. 1988; Mantegazza et al. 1988).  The clinician and the patient then need to 
consider immunosuppressant therapy, and here the evidence base relies on data from the 
generalized disease and expert opinion. For generalized MG, cyclosporine, tacrolimus, and 
mycophenolate mofetil have steroid sparing effects demonstrated in double-blind, placebo-
controlled or retrospective studies (Sanders and Evoli 2010). 
6. Conclusion 
The analysis provides a focused review of clinical manifestations, diagnosis, and treatment 
of OM and highlights the significant limitations of the literature. Diagnosis of OM is 
generally straightforward, when the clinician thinks of the disorder. Confirmation of clinical 
diagnosis is challenging for OM. Serum AChR antibodies are found in only half of patients, 
and while the MuSK antibody is detected in about three percent of the generalized MG 
population, it is found only rarely among patients with isolated OM. Therefore the majority 
of patients lack detectable autoantibodies and confirmation of a neuromuscular 
transmission disorder relies on specialized, electrophysiological testing. Although expert 
opinion suggests that treatment is highly effective, significant knowledge gaps exist as to 
severity of treatment complications and over-all quality of life of patients with OM. Only 
through prospective trials or multi-center, rigorously constructed outcome databases will 
improvements in treatment be achieved. 
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